Cargando…
An experience with ibrutinib monotherapy for Richter’s syndrome isolated in the central nervous system
Richter’s syndrome (RS) of the central nervous system (CNS) is known to have an extremely poor prognosis. Ibrutinib has been reported to have some activity in patients with RS, despite its poor prognosis. Although ibrutinib crosses the blood-brain barrier, its efficacy in RS patients with CNS involv...
Autores principales: | Nato, Yuma, Nagaharu, Keiki, Inoue, Kanako, Yabu, Kodai, Sawaki, Akihiko, Shiotani, Takuya, Kageyama, Yuki, Tanaka, Ken, Ohshima, Koichi, Miyashita, Hiroyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JSLRT
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898719/ https://www.ncbi.nlm.nih.gov/pubmed/36436931 http://dx.doi.org/10.3960/jslrt.22017 |
Ejemplares similares
-
Sézary Syndrome with CD4/CD8 Double-Negative Neoplastic T Cells in Peripheral Blood
por: Kageyama, Yuki, et al.
Publicado: (2021) -
Ibrutinib has some activity in Richter's syndrome
por: Giri, S, et al.
Publicado: (2015) -
Ibrutinib and rituximab induced rapid response in refractory Richter syndrome
por: Lamar, Zanetta, et al.
Publicado: (2015) -
A Novel SPTA1 Mutation in a Patient with Hereditary Spherocytosis without a Family History and Coexisting Gilbert's Syndrome
por: Nato, Yuma, et al.
Publicado: (2022) -
Hodgkin's variant of Richter transformation during ibrutinib therapy: A case report and review of the literature
por: Afonso, Carolina, et al.
Publicado: (2022)